A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
A Real-world Observational Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients With Advanced Colorectal Cancer
Sponsor: China Medical University, China
Listed as NCT06169202, this observational or N/A phase trial focuses on Capecitabine and Fruquintinib and remains ongoing. Sponsored by China Medical University, China, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jan 2024 — Jul 2024 [monthly]
Recruiting
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- China Medical University, China
For direct contact, visit the study record on ClinicalTrials.gov .